Rapid improvement of prurigo nodularis with cyclosporine treatment
To the Editor: Prurigo nodularis (PN) is a chronic skin condition characterized by pruritic nodules, representing the end-stage cutaneous changes of scratching secondary to itch. The underlying etiology remains elusive, as does the inciting cause of the itch. Some have postulated that neurotransmitters, which affect mood also modulate patients' perception of itch through descending spinal pathways. PN is often refractory to topical corticosteroids and calcineurin inhibitors, and many patients require systemic treatment. There are few studies to guide further therapy. In 1995, Berth-Jones et al observed that PN might respond to cyclosporine, 2 which was also observed in another study. 3 Treatment with cyclosporine has been associated with adverse events, including creatinine elevation, hypertension, gastric upset, muscle pains, angioedema, gingival hyperplasia, and neuropathy. 4 Siepmann et al published a report on a series of 14 patients treated with cyclosporine showing a significant response in 13 patients, 7 of whom experienced the aforementioned side effects. 5 We present a retrospective chart review of PN patients seen in the academic medical centerebased practices of 2 physicians (Drs Orlow and Cohen) from 2005-2015 that illustrates the rapid improvement cyclosporine can afford patients with PN.
We obtained institutional review board approval (S14-01982). A retrospective chart review was performed for patients with a diagnosis of PN or lichen simplex seen at the academic medical centerebased practices of 2 attending physicians (Drs Orlow and Cohen) from 2005-2015. Patients treated with cyclosporine were included, and charts were reviewed to exclude those without clear diagnoses or treated with other therapies. Data regarding patient age, length of and dosing of cyclosporine treatment, side effects attributed to cyclosporine, whether or not remission was achieved, and time to remission were collected.
In all, 76 patient charts were reviewed; 8 patients qualified for inclusion, 5 of which were female (Table I ). The average age was 57 years. With the pediatric patient excluded, the average age of included adults was 64 years.
Patients were counseled regarding possible side effects and the need for laboratory and blood pressure monitoring. The average dose of cyclosporine was 3.1 mg/kg, and the average time until improvement was ;3 weeks. Patients reported fewer new lesions, decreased pruritus, and resolution of existing lesions.
Four patients had complications attributed to cyclosporine, which included migraines, nausea, hypertension, dizziness, blurry vision, keratoacanthoma, hypercholesterolemia, and folliculitis. None had an elevation in creatinine. Six patients achieved remission, 1 was lost to follow-up, and the final patient reported significant improvement but not remission. No patients reported recurrence upon treatment discontinuation.
Limitations include the study's small sample size, retrospective nature, and the patient population being from 1 academic medical center. PN is difficult to treat, with many patients refractory to first-line topical or phototherapy. We suggest cyclosporine as a first-line systemic therapy for severe, recalcitrant disease, with the plan to transition to topical or phototherapy over the course of 3-6 months. Cyclosporine would not be recommended for PN patients with impaired renal function. Given the aforementioned side effect profile, patients must be appropriately selected and willing to undergo regular monitoring. In our experience, PN can rapidly improve with cyclosporine treatment. Efficacy and rapid activity of omalizumab retreatment in chronic spontaneous urticaria
To the Editor: The efficacy and safety of omalizumab for the adjunctive treatment of chronic spontaneous urticaria (CSU) is well documented. [1] [2] [3] [4] However, many patients experience disease flare-ups at variable intervals after their last omalizumab dose, and
